Microbiologic characterization of isolates from a dalbavancin clinical trial for catheter-related bloodstream infections

Diagnostic Microbiology and Infectious Disease

Volumn 54, Issue 2, 2006, Pages 83-87

  Goldstein, Beth P ^a   Jones, Ronald N ^b,c   Fritsche, Thomas R ^b   Biedenbach, Douglas J ^b  

^a Vicuron Pharmaceuticals   (United States)

^b JMI LABORATORIES   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteremia; Catheters; Coagulase negative staphylococci; Dalbavancin; Molecular typing; PFGE

Indexed keywords

AMPICILLIN; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; TEICOPLANIN; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; BLOOD FLOW; CATHETER INFECTION; CLINICAL PRACTICE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; GENETIC TRAIT; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETERIZATION; DNA, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RANDOMIZED CONTROLLED TRIALS; TEICOPLANIN; VANCOMYCIN;

EID: 31744439436     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2005.09.004     Document Type: Article

References (28)

1. M. Buckwalter, and J.A. Dowell Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide J. Clin. Pharmacol. 2005 (in press)
2. G. Candiani, M. Abbondi, M. Borgonovi, G. Romanò, and F. Parenti In vitro and in vivo antibacterial activity of BI397, a new semi-synthetic glycopeptide antibiotic J. Antimicrob. Chemother. 44 1999 179 192
3. Centers for Disease Control and Prevention National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999 Am. J. Infect. Control 27 1999 520 532
4. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. Document M100-S15 2005 CLSI Wayne (PA)
5. L.M. Deshpande, T.R. Fritsche, and R.N. Jones Molecular epidemiology of selected multidrug-resistant bacteria: A global report from the SENTRY Antimicrobial Surveillance Program Diagn. Microbiol. Infect. Dis. 49 2004 231 236
6. M.B. Edmond, S.E. Wallace, D.K. McClish, M.A. Pfaller, R.N. Jones, and R.P. Wenzel Nosocomial bloodstream infections in United States hospitals: A three-year analysis Clin. Infect. Dis. 29 1999 239 244
7. J. Ena, R.W. Dick, R.N. Jones, and R.P. Wenzel The epidemiology of intravenous vancomycin usage in a university hospital: A 10-year study JAMA 269 1993 598 602
8. D. Jabes, G. Candiani, G. Romanò, C. Brunati, S. Riva, and M. Cavaleri Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model Antimicrob. Agents Chemother. 48 2004 1118 1123
9. R.N. Jones, D.J. Biedenbach, D.M. Johnson, and M.A. Pfaller In vitro evaluation of BI397, a novel glycopeptide antimicrobial agent J. Chemother. 13 2001 244 254
10. R.N. Jones, J.M. Streit, and T.R. Fritsche Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide Int. J. Antimicrob. Agents 23 2004 197 199
11. A. Lefort, J. Pavie, L. Garry, F. Chau, and B. Fantin Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin Antimicrob. Agents Chemother. 48 2004 1061 1064
12. A. Leighton, A.B. Gottlieb, M.B. Dorr, D. Jabes, G. Mosconi, C. VanSanders, E.J. Mroszczak, K.C. Campbell, and E. Kelly Tolerability, pharmacokinetics and pharmacodynamics of intravenous dalbavancin in healthy volunteers Antimicrob. Agents Chemother. 48 2004 940 945
13. G. Lin, K. Credito, L.M. Ednie, and P.C. Appelbaum Antistaphylococcal activity of dalbavancin, an experimental glycopeptide Antimicrob. Agents Chemother. 49 2005 770 772
14. S. Lopez, C. Hackbarth, G. Romanò, J. Trias, D. Jabes, and B.P. Goldstein In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide J. Antimicrob. Chemother. 55 Suppl S2 2005 ii21 ii24
15. A. Malabarba, and B.P. Goldstein Origin, structure and activity in vitro and in vivo of dalbavancin J. Antimicrob. Chemother. 55 Suppl S2 2005 ii15 ii20
16. D.C. McGee, and M.K. Gould Preventing complications of central venous catheterization N. Engl. J. Med. 348 2003 1123 1133
17. L.A. Mermel, B.M. Farr, R.J. Sherertz, I.I. Raad, N. O'Grady, and J.S. Harris Guidelines for the management of intravascular catheter-related infections Clin. Infect. Dis. 32 2001 1249 1272
18. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A6 2003 NCCLS Wayne (PA)
19. N.P. O'Grady, M. Alexander, E.P. Dellinger, J.L. Gerberding, S.O. Heard, D.G. Maki, H. Masur, R.D. McCormick, L.A. Mermel, M.L. Pearson, I.I. Raad, A. Randolph, and R.A. Weinstein Guidelines for the prevention of intravascular catheter-related infections Clin. Infect. Dis. 35 2002 1281 1307
20. S.J. Pelletier, T.D. Crabtree, T.G. Gleason, T.L. Pruett, and R.G. Sawyer Bacteremia associated with central venous catheter infection is not an independent predictor of outcomes J. Am. Coll. Surg. 190 2000 671 681
21. M.A. Pfaller, J. Acar, R.N. Jones, J. Verhoef, J. Turnidge, and H.S. Sader Integration of molecular characterization of microorganisms in a global antimicrobial resistance surveillance program Clin. Infect. Dis. 32 Suppl 2 2001 S156 S167
22. I. Raad, R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, H. Hanna, B. Goldstein, T. Henkel, and E. Seltzer Efficacy and safety of weekly dalbavancin in the treatment of catheter-related bloodstream infections Clin. Infect. Dis. 40 2005 374 380
23. M.K. Schinabeck, and M.A. Ghannoum Catheter-related infections-diagnosis, treatment and prevention Clin. Microbiol. Newsl. 25 2003 113 118
24. E. Seltzer, M.B. Dorr, B.P. Goldstein, M. Perry, J.A. Dowell, and T. Henkel Once-weekly dalbavancin versus standard of care antimicrobial regimens for treatment of skin and soft tissue infections Clin. Infect. Dis. 37 2003 1298 1303
25. J.H. Sloos, L. Dijkshoorn, L. Vogel, and C.P.A. Van Boven Performance of phenotypic and genotypic methods to determine the clinical relevance of serial blood isolates of Staphylococcus epidermidis in patients with septicemia J. Clin. Microbiol. 38 2000 2488 2493
26. J.M. Streit, T.R. Fritsche, H.S. Sader, and R.N. Jones Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates Diagn. Microbiol. Infect. Dis. 48 2004 137 143
27. F.C. Tenover, R.D. Arbeit, R.V. Goering, P.A. Michelsen, B.E. Murray, D.H. Persing, and B. Swaminathan Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: Criteria for bacterial strain typing J. Clin. Microbiol. 33 1995 2233 2239
28. N. Woodford Novel agents for the treatment of resistant Gram-positive infections Expert Opin. Investig. Drugs 12 2003 117 137